“Twice daily oral administration of tucatinib was assessed in repeat-dose toxicity studies for up to 3 months in rats and monkeys, consistent with the clinical route of administration and intended dosing schedule.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Why that species
Sequence homology, historical use (rat) and higher oral tolerability (monkey)
“The pharmacological relevance of the toxicological species was discussed by the applicant and taking sequence homology information as well as a justification based on historical use (rat) and higher oral tolerability (monkey) into account, the chosen species were considered acceptable.”
“In a 90-day cynomolgus monkey study, males and females (6/sex/group) were administered tucatinib at 0, 2.5, 10, or 20 mg/kg/dose twice daily (5, 20, or 40 mg/kg/day) via oral gavage.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗